Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, ...
The development could help scientists develop patient-specific treatments and one day offer a lab-grown lung transplant ...
Mayo Clinic researchers have identified a molecular "switch" in lung cells that helps them decide when to repair tissue and ...
Asianet Newsable on MSN
Scientists Reveal Lung Self-Healing Switch, Offering Hope for Chronic Lung Disease
Scientists uncover a molecular “switch” in lung cells that controls repair vs. defense. Targeting it could boost tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback